Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia

References

• Anon. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. J Am Med Assoc 1984;251:351–64
   Web of Science ®Google Scholar
• American Heart Association. Heart and stroke facts. Statistical supplement. Dallas (TX); 2000
   Google Scholar
• Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial 1 – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149–58
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New Engl J Med 2005;352:1425–35
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685–96
   PubMed Web of Science ®Google Scholar
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–78
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia [West of Scotland Coronary Prevention Study Group]. New Engl J Med 1995;333:1301–7
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. J Am Med Assoc 2006;295:180–9
   PubMed Web of Science ®Google Scholar
• Vasudevan AR, Jones PH. Effective use of combination lipid therapy. Curr Atheroscler Rep 2006;8:76–84
   PubMedGoogle Scholar
• Hoerger TJ, Bala MV, Bray JW, et al. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am J Cardiol 1998;82:61–5
   PubMed Web of Science ®Google Scholar
• Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs – do rates reported in clinical trials reflect rates in primary care settings? New Engl J Med 1995;332:1125–31
   PubMed Web of Science ®Google Scholar
• Avorn J, Monette J, Lacour A, et al. Persistence of use of lipidlowering medications: a cross-national study. J Am Med Assoc 1998;279:1458–62
   PubMed Web of Science ®Google Scholar
• Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Med 1996;100:197–204
   PubMed Web of Science ®Google Scholar
• Vega GL, Grundy SM. Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol. J Am Med Assoc 1987;257:33–8
   PubMed Web of Science ®Google Scholar
• Galin ID, Smith DA. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) Study. Am Heart J 2006;151:e1
   PubMedGoogle Scholar
• Ballantyne CM, Weiss R, Moccetti T, et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol 2007;99:673–80
   PubMed Web of Science ®Google Scholar
• Catapano AL, Davidson MH, Ballantyne CM, et al. Lipidaltering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin 2006;22:2041–53
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Guyton JR, Mazzone T, et al. Ezetimibe/ simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin Proc 2006;81:1579–88
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. J Am Med Assoc 2005;294:2437–45
   PubMed Web of Science ®Google Scholar
• de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. J Am Med Assoc 2004;292:1307–16
   PubMed Web of Science ®Google Scholar
• Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother 1995;29:743–59
   Google Scholar
• Grundy SM, Ahrens Jr EH, Salen G. Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. J Lab Clin Med 1971;78:94–121
   PubMed Web of Science ®Google Scholar
• Einarsson K, Ericsson S, Ewerth S, et al. Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism. Eur J Clin Pharmacol 1991;40(Suppl 1):S53–S58
   PubMedGoogle Scholar
• Chiang JY. Bile acid regulation of gene expression: roles of nuclear hormone receptors. Endocr Rev 2002;23:443–63
   PubMed Web of Science ®Google Scholar
• Shepherd J, Packard CJ, Bicker S, et al. Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. New Engl J Med 1980;302:1219–22
   PubMed Web of Science ®Google Scholar
• Schwartz CC, Halloran LG, Vlahcevic ZR, et al. Preferential utilization of free cholesterol from high-density lipoproteins for biliary cholesterol secretion in man. Science 1978; 200:62–4
   PubMed Web of Science ®Google Scholar
• Bravo E, Cantafora A, Argiolas L. Hepatic uptake and metabolism of free cholesterol from different lipoprotein classes. An in vivo study in the rat. Biochim Biophys Acta 1989;1003:315–20
   Google Scholar
• Robins SJ, Fasulo JM. High density lipoproteins, but not other lipoproteins, provide a vehicle for sterol transport to bile. J Clin Invest 1997;99:380–4
   PubMed Web of Science ®Google Scholar
• Schwartz CC, Vlahcevic ZR, Halloran LG, et al. Evidence for the existence of definitive hepatic cholesterol precursor compartments for bile acids and biliary cholesterol in man. Gastroenterology 1975;69:1379–82
   PubMed Web of Science ®Google Scholar
• WelChol (colesevelam hydrochloride) Prescribing Information v8. Sankyo Pharma Inc, Parsippany (NJ). Available at www. welchol.com [accessed on January 12, 2008).
   Google Scholar
• Insull Jr W. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J 2006;99:257–73
   PubMed Web of Science ®Google Scholar
• Claudel T, Staels B, Kuipers F. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol 2005;25:2020–30
   Google Scholar
• Lehmann JM, Kliewer SA, Moore LB, et al. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem 1997;272:3137–40
   PubMed Web of Science ®Google Scholar
• Cariou B, Duran-Sandoval D, Kuipers F, Staels B. Farnesoid X receptor: a new player in glucose metabolism? Endocrinology 2005;146:981–3
   PubMed Web of Science ®Google Scholar
• Chiang JY, Kimmel R, Weinberger C, Stroup D. Farnesoid X receptor responds to bile acids and represses cholesterol 7-alpha-hydroxylase gene (CYP7A1) transcription. J Biol Chem 2000;275:10918–24
   PubMed Web of Science ®Google Scholar
• Claudel T, Sturm E, Duez H, et al. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest 2002;109:961–71
   PubMed Web of Science ®Google Scholar
• Brendel C, Schoonjans K, Botrugno OA, et al. The small heterodimer partner interacts with the liver X receptor alpha and represses its transcriptional activity. Molec Endocrinol 2002;16:2065–76
   PubMed Web of Science ®Google Scholar
• Watanabe M, Houten SM, Wang L, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004;113:1408–18
   PubMed Web of Science ®Google Scholar
• Davidson MH, Dittakavi V, Bandari A, et al. Colesevelam HCl decreases atherosclerosis and may activate reverse cholesterol transport in cholesterol-fed rabbits. J Appl Res 2006;6:4–13
   Google Scholar
• Davidson MH. The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review. Expert Opin Pharmacother 2007;8:2569–78
   PubMed Web of Science ®Google Scholar
• Braunlin W, Zhorov E, Smisek D, et al. In vitro comparison of bile acid binding to colesevelam HCl and other bile acid sequestrants. Polymer Reprints 2000;41:708–9
   Google Scholar
• Bays H, Dujovne C. Colesevelam HCl: a non-systemic lipidaltering drug. Expert Opin Pharmacother 2003;4:779–90
   PubMed Web of Science ®Google Scholar
• Aldridge MA, Ito MK. Colesevelam hydrochloride: a novel bile acid-binding resin. Ann Pharmacother 2001;35:898–907
   PubMed Web of Science ®Google Scholar
• Mandeville WH, Goldberg DI. The sequestration of bile acids, a non-absorbed method for cholesterol reduction: a review. Curr Pharm Des 1997;3:15–28
   Web of Science ®Google Scholar
• Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999;159:1893–900
   PubMed Web of Science ®Google Scholar
• Insull Jr W, Toth P, Mullican W, et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin Proc 2001;76:971–82
   PubMed Web of Science ®Google Scholar
• Rosenson RS. Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. Atherosclerosis 2006;185:327–30
   PubMed Web of Science ®Google Scholar
• Devaraj S, Autret B, Jialal I. Effects of colesevelam hydrochloride (WelChol) on biomarkers of inflammation in patients with mild hypercholesterolemia. Am J Cardiol 2006;98:641–3
   Google Scholar
• Knapp HH, Schrott H, Ma P, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 2001;110: 352–60
   PubMed Web of Science ®Google Scholar
• Bays HE, Davidson M, Jones MR, Abby SL. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol 2006;97: 1198–205
   PubMed Web of Science ®Google Scholar
• Hunninghake D, Insull Jr W, Toth P, et al. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 2001;158:407–16
   PubMed Web of Science ®Google Scholar
• McKenney J, Jones M, Abby S. Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia. Curr Med Res Opin 2005;21:1403–12
   Google Scholar
• Zema MJ. Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia. Am J Ther 2005;12:306–10
   PubMedGoogle Scholar
• Bays H, Rhyne J, Abby S, et al. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. Curr Med Res Opin 2006;22:2191–200
   PubMed Web of Science ®Google Scholar
• Rivers SM, Kane MP, Busch RS, et al. Colesevelam hydrochloride–ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance. Endocr Pract 2007;13:11–6
   PubMedGoogle Scholar
• Knopp RH, Tsunehara C, Retzlaff BM, et al. Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study. Metabolism 2006;55:1697–703
   PubMed Web of Science ®Google Scholar
• Gazi IF, Mikhailidis DP. Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview. Expert Opin Ther Targets 2006;10:851–66
   PubMed Web of Science ®Google Scholar
• Liberopoulos EN, Daskalopoulou SS, Mikhailidis DP, et al. A review of the lipid-related effects of fluvastatin. Curr Med Res Opin 2005;21:231–44
   PubMed Web of Science ®Google Scholar
• Genzyme Corp announces launch of Cholestagel in Europe – Topix. Available at www.topix.com [last accessed January 12, 2008]
   Google Scholar
• STEPS-July 15, 2005 – American family physician. Available at www.aafp.org/afp/20050715/steps.html [last accessed January 12, 2008]
   Google Scholar
• Superko HR, Greenland P, Manchester RA, et al. Effectiveness of low-dose colestipol therapy in patients with moderate hypercholesterolemia. Am J Cardiol 1992;70:135–40
   PubMed Web of Science ®Google Scholar
• Schectman G, Hiatt J, Hartz A. Evaluation of the effectiveness of lipid-lowering therapy (bile acid sequestrants, niacin, psyllium and lovastatin) for treating hypercholesterolemia in veterans. Am J Cardiol 1993;71:759–65
   Google Scholar
• Kalogirou M, Tsimihodimos V, Gazi I, et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin 2007;23:1169–76
   PubMed Web of Science ®Google Scholar
• Knopp RH, Gitter H, Truitt T, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003;24:729–41
   PubMed Web of Science ®Google Scholar
• Donovan JM, Von Bergmann K, Setchell KDR, et al. Effects of colesevelam HCl on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. Dig Dis Sci 2005;50:1232–8
   PubMed Web of Science ®Google Scholar
• Davidson MH, Toth P, Weiss S, et al. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol 2001;24:467–74
   PubMed Web of Science ®Google Scholar
• Mikhailidis DP, Sibbring GC, Ballantyne CM, et al. Metaanalysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007;23:2009–26
   PubMed Web of Science ®Google Scholar
• Florentin M, Liberopoulos EN, Elisaf MS. Ezetimibe-associated adverse effects: what the clinician needs to know. Int J Clin Pract 2008;62:88–96
   Google Scholar
• Farnier M, Freeman MW, Macdonell G, et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J 2005;26:897–905
   PubMed Web of Science ®Google Scholar
• Xydakis AM, Guyton JR, Chiou P, et al. Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. Am J Cardiol 2004;94:795–7
   PubMed Web of Science ®Google Scholar
• Jakulj L, Trip MD, Sudhop T, et al. Inhibition of cholesterol absorption by the combination of dietary plant sterols and ezetimibe: effects on plasma lipid levels. J Lipid Res 2005;46:2692–8
   PubMed Web of Science ®Google Scholar
• Bays HE, Abby S, Truitt K, Jones MR. Colesevelam HCl reduces cholesterol and glucose levels when added to metformin-based therapy in patients with type 2 diabetes mellitus (Abstract). J Clin Lipidol 2007;1:505
   Google Scholar
• Jones MR, Abby S, Truitt K. Colesevelam HCl is an effective and safe add-on to insulin-based therapy in patients with type 2 diabetes mellitus (Abstract). J Clin Lipidol 2007;1: 504
   Google Scholar
• Ganda OP, Abby S, Truitt K, Jones MR. Colesevelam HCl is an effective and safe add-on to sulfonylurea-based therapy in patients with type 2 diabetes mellitus (Abstract). J Clin Lipidol 2007;1:504
   Google Scholar
• Resnick HE, Harris MI, Brock DB, Harris TB. American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular disease risk profiles: results from the Third National Health and Nutrition Examination Survey. Diabetes Care 2000;23:176–80
   PubMed Web of Science ®Google Scholar
• Zieve FJ, Kalin MF, Schwartz SL, et al. Results of the glucoselowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 2007;29:74–83
   PubMed Web of Science ®Google Scholar
• Tsimihodimos V, Gazi I, Kostara C, et al. Plasma lipoproteins and triacylglycerol are predictors of small, dense LDL particles. Lipids 2007;42:403–9
   PubMed Web of Science ®Google Scholar
• Gazi I, Tsimihodimos V, Filippatos T, et al. Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. Metabolism 2006;55:885–91
   PubMed Web of Science ®Google Scholar
• Blake GJ, Otvos JD, Rifai N, Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 2002;106:1930–7
   PubMed Web of Science ®Google Scholar
• Jialal I, Devaraj S. Inflammation and atherosclerosis: the value of the high-sensitivity C-reactive protein assay as a risk marker. Am J Clin Pathol 2001;116(Suppl):S108–S115
   Google Scholar
• Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. New Engl J Med 2005;352:20–8
   PubMed Web of Science ®Google Scholar
• Rizos E, Bairaktari E, Ganotakis E, et al. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes. J Cardiovasc Pharmacol Ther 2002;7:219–26
   PubMedGoogle Scholar
• Rizos E, Kostoula A, Elisaf M, Mikhailidis DP. Effect of ciprofibrate on C-reactive protein and fibrinogen levels. Angiology 2002;53:273–7
   PubMed Web of Science ®Google Scholar
• Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. New Engl J Med 1990;323:1289–98
   PubMed Web of Science ®Google Scholar
• Gazi IF, Daskalopoulou SS, Nair DR, Mikhailidis DP. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin 2007;23:2183–92
   PubMed Web of Science ®Google Scholar
• Davidson MH, Stein EA, Hunninghake DB, et al. Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide longterm experience in patients with hypercholesterolemia. Nutr Metab Cardiovasc Dis 2000;10:253–62
   PubMed Web of Science ®Google Scholar
• Foley KA, Simpson Jr RJ, Crouse 3rd JR, et al. Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol 2003;92:79–81
   Google Scholar
• Evans M, Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf 2002;25:649–63
   PubMed Web of Science ®Google Scholar
• Silva M, Matthews ML, Jarvis C, et al. Meta-analysis of druginduced adverse events associated with intensive-dose statin therapy. Clin Ther 2007;29:253–60
   PubMed Web of Science ®Google Scholar
• Mackie BD, Satija S, Nell C, et al. Monday, Wednesday, and Friday dosing of rosuvastatin in patients previously intolerant to statin therapy. Am J Cardiol 2007;99:291
   PubMed Web of Science ®Google Scholar
• Zhao XQ, Phan BA, Chu B, et al. Testing the hypothesis of atherosclerotic plaque lipid depletion during lipid therapy by magnetic resonance imaging: study design of Carotid Plaque Composition Study. Am Heart J 2007;154: 239–46
   PubMed Web of Science ®Google Scholar
• Effects of metformin HCl in combination with colesevelam HCl, compared to metformin HCl alone, as initial therapy in drug naive subjects with type 2 diabetes mellitus, and the effects of colesevelam HCl on the lipid profile in subjects with pre diabetes. Available at http://clinicaltrials.gov/show/ NCT00570739 [last accessed January 12, 2008]
   Google Scholar
• Colesevelam HCl administered to pediatric patients with heterozygous familial hypercholesterolemia on a stable dose of statins or treatment naive to lipid-lowering therapy Available at http://www.clinicaltrials.gov/ct/show/NCT00145574 [last accessed January 12, 2008]
   Google Scholar
• Donovan JM, Stypinski D, Stiles MR, et al. Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. Cardiovasc Drugs Ther 2000;14:681–90
   PubMed Web of Science ®Google Scholar
• Ast M, Frishman WH. Bile acid sequestrants. J Clin Pharmacol 1990;30:99–106
   PubMed Web of Science ®Google Scholar
• Pregnancy and the drug dilemma. Available at www.fda.gov [last accessed January 12, 2008]
   Google Scholar